SINGAPORE, Nov 8 (Bernama-GLOBE NEWSWIRE) — Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, today announced the execution of an exclusive agreement with Baylor College of Medicine for worldwide commercial rights to the allogeneic Epstein-Barr virus specific T-cell (EBVST) technology platform developed jointly by Tessa’s Scientific Co-Founder, Malcolm Brenner, M.D., Ph.D., and his colleagues Cliona Rooney Ph.D. and Helen Heslop M.D., D.Sc. at Baylor College of Medicine. Tessa is currently advancing a pipeline of products that utilize CD30.CAR-modified EBVSTs, including its lead allogeneic cell therapy, TT11X, which is being co-developed for the treatment of relapsed or refractory CD30-positive lymphomas.
- November 8, 2022
0
267
Less than a minute
You can share this post!
administrator
Related Articles
LYB lays foundation for 1st industrial-scale advanced recycling…
- September 20, 2024
EBC Bags BrokersView Best Trading Experience Award, Strengthening…
- September 20, 2024
Menlo Security Named a Leader in GigaOm Radar…
- September 20, 2024